Doppler ultrasound is one of the oldest modalities for measuring and visualizing blood flow. This review paper explores the principles of Doppler ultrasound and blood flow imaging. Following a brief history of Doppler ultrasound, all Doppler modes, including B-Flow imaging, are discussed, with emphasis on spectral broadening and Doppler spectrum amplitude in relation to clinical implications. The paper also outlines sources of uncertainty in Doppler flow measurement. Emerging technologies in blood flow imaging are introduced, including microvascular flow imaging without contrast agents and four-dimensional vascular imaging from a two-dimensional transducer, which have been commercialized within the past decade, as well as row-column array transducer systems, high-frame-rate imaging, and photoacoustic imaging, which remain in preclinical and research stages.
The blood–brain barrier (BBB) severely restricts the delivery of neuroprotective compounds to the brain, limiting therapeutic strategies for Parkinson’s disease (PD). Ginsenoside Rg3, a bioactive component of ginseng, has demonstrated neuroprotective potential, but its efficacy is constrained by poor BBB permeability. Here, we evaluated focused ultrasound (FUS)-mediated BBB opening (FUS BBBO) to enhance delivery of Rg3-loaded nanoparticles in a rotenone-induced mouse model of PD. Localized FUS sonication were applied to induce transient BBB disruption, followed by intraperitoneal administration of FITC-labeled Rg3 nanoparticles. In vivo fluorescence imaging confirmed a significant increase in brain accumulation of nanoparticles after FUS BBBO. While Rg3 nanoparticle treatment alone moderately increased ATP levels and Complex I activity, FUS alone produced a similar but slightly higher recovery. In contrast, the combination treatment with FUS-mediated BBBO achieved the most significant recovery (ATP: 0.27 ± 0.06, p < 0.01 vs. PD; Complex I: 1.98 ± 0.41, p < 0.05 vs. PD) and markedly improved motor performance compared with all other groups. These results demonstrate that FUS BBBO can effectively enhance targeted delivery of Rg3 nanoparticles to the brain, thereby restoring mitochondrial function and improving PD-associated motor deficits and locomotor performance. This noninvasive approach demonstrates that FUS BBBO can significantly enhance the therapeutic efficacy of Rg3 nanoparticles, offering a promising strategy for PD treatment.